Antipalúdicos: actualización de su uso en enfermedades reumáticas

Page, 1951, Treatment of lupus erythematosus with mepacrine, Lancet, 2, 755, 10.1016/S0140-6736(51)91643-1 Wallace, 1996, The History of antimalarial, Lupus, 5, S2, 10.1177/096120339600500102 Wallace, 2000, Is there a role for quinacrina (Atabrine) in the new millennium, Lupus, 9, 81, 10.1191/096120300678828163 Toubi, 2000, The benefit ofcombining hydroxychloroquine with quinacrine in the treatment of SLE patients, Lupus, 9, 92, 10.1191/096120300678828082 Scherbel, 1958, Further observations on the use of 4-aminoquinoline compounds in patients with rheumatoid arthritis related diseases, Cleve Clin Q, 25, 95, 10.3949/ccjm.25.2.95 Furst, 1996, Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases, Lupus, 5, S11, 10.1177/096120339600500104 Munster, 2002, Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis, Arthritis Rheum, 46, 1460, 10.1002/art.10307 Landewe, 1995, Antimalarial drug induced decrease in creatinine clearance, J Rheumatol, 22, 34 Rubin, 1962, Studies on the pharmacology of chloroquine, Arch Ophthalmol, 70, 474, 10.1001/archopht.1963.00960050476009 Aponte, 1992, Liver enzyme levels in artritis patirnts treated with long-term bolus methotrexate, Arthritis Rheum, 35, 126, 10.1002/art.1780350123 Jewell, 2000, Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment, J Am Acad Dermatol, 42, 983, 10.1016/S0190-9622(00)90290-1 Pool, 1981, Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages, J Cell Biol, 90, 665, 10.1083/jcb.90.3.665 Fox, 1993, Mechanism of action of hydroxychloroquine as an antirheumatic drug, Sem Arthritis Rheum, 23, 82, 10.1016/S0049-0172(10)80012-5 Fox, 1996, Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drugs development, Lupus, 5, S4, 10.1177/096120339600500103 Rynes, 1997, Antimalarial drugs in the treatment of rheumatological diseases, J Rheumatol, 36, 799, 10.1093/rheumatology/36.7.799 Bondeson, 1998, Antimalarial drugs inhibit phospholipase A2 activation and induction of interleuk in 1β and tumor necrosis factor a inmacrophages: implications for their mode of action in rheumatoid arthritis, Gen Pharmac, 30, 357, 10.1016/S0306-3623(97)00269-3 Murphy, 1987, Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring, Brit J Dermatol, 116, 379, 10.1111/j.1365-2133.1987.tb05852.x Wozniacka, 2000, Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit, Lupus, 11, 71, 10.1191/0961203302lu147rr Nguyen, 1998, 4-aminoquinoline antimalarials enhance UV-B induced c-jun transcriptional activation, Lupus, 7, 148, 10.1191/096120398678919912 Lafont, 1984, Influence of acute injection of chloroquine on the biliary secretion of lipids and lysosomal enzyme on rats, Lipids, 19, 195, 10.1007/BF02534797 Goldstein, 1975, Inhibition of ptoteolytic degradation of low density lipoprotein in human fibroblasts by chloroquine, concanavalin A and Triton WR 1339, J Biol Chem, 250, 7854, 10.1016/S0021-9258(19)40894-6 Chen, 1984, Chloroquine inhibits cyclization of squaleneoxide to lanosterol in mammalians cells, J Biol Chem, 259, 8156, 10.1016/S0021-9258(17)39707-7 Beynen, 1981, Inhibition of hepaticcolesterol síntesis by chloroquine, Lipids, 16, 472, 10.1007/BF02535017 Svenson, 1987, Serum lipoprotein inactive rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment, Arch Intern Med, 147, 1917, 10.1001/archinte.1987.00370110045006 Wallace, 1990, Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids, Am J Med, 89, 322, 10.1016/0002-9343(90)90345-E Tam, 2000, Hydroxychloroquine has nosignificant effect on lipids and apolipo proteins in Chinese systemic lupus erythematosus patients with mild or inactive disease, Lupus, 9, 413, 10.1191/096120300678828541 Hodis, 1993, The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus, J Rheumatol, 20, 661 Petri, 1994, Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupuserythematosus: a longitudinal data análisis, Am J Med, 96, 254, 10.1016/0002-9343(94)90151-1 Kavanaugh, 1997, Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus, J Clin Rheumatol, 3, 3, 10.1097/00124743-199702000-00002 Munro, 1997, Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis, Ann Rheum Dis, 56, 374, 10.1136/ard.56.6.374 Rahman, 1999, The cholesterol lowering effect of antimal arial drugs is enhanced in patients with lupus taking corticosteroid drugs, J Rheumatol, 26, 325 Tam, 2000, Effect ofantimal arial agents on the fasting lipid profile in systemic lupus erythematosus, Rheumatol, 27, 2142 Borba, 2001, Longterm beneficial effect of choloroquine diphosphateon lipoprotein profile in lupus patients with and without steroidtherapy, J Rheumatol, 28, 780 Phillips, 1986, Hypoglycemia and antimal arial drugs: quinidine and release of insulin, BMJ, 292, 1319, 10.1136/bmj.292.6531.1319 Quatraro, 1990, Hydroxychloroquine in decompensated treatment-refractory noninsulin- dependent diabetes mellitus. A new job for an old drug?, Ann Intern Med, 112, 678, 10.7326/0003-4819-112-9-678 Petri, 1996, Hydroxychloroquine use in the Baltimore lupus cohort: effects on lipids, glucose and thrombosis, Lupus, 5, S16, 10.1177/096120339600500105 Shojania, 1999, Hypoglycemia induced by hydroxychloroquinein a type II diabetic treated for polyarthritis, J Rheumatol, 26, 195 Loudon, 1988, Hydroxychloroquine and postoperative thromboembolism after total hip replacement, Am J Med, 85, 57, 10.1016/0002-9343(88)90364-6 Carter, 1971, Prevention of post-operative deep venous thrombosis and pulmonary embolism, BMJ, 1, 312, 10.1136/bmj.1.5744.312 Carter, 1974, Prevention of postoperative deep venous trombosis in legs by orally administered hydroxychloroquine sulfate, BMJ, 3, 94, 10.1136/bmj.3.5923.94 Pilcher, 1975, Hydroxychloroquine sulfate in prevention of thromboembolic phenomena in surgical patients, Am Surgeon, 41, 761 Hansen, 1976, Hydroxychloroquine sulphate in prevention of deep venous thrombosis following of the hip, pelvis, or thoracolumbar spine, J Bone Joint Surg Am, 58, 1089, 10.2106/00004623-197658080-00008 Chrisman, 1976, Prevention of venous thromboembolism by administration of hydroxychloroquine, J Bone Joint Surg Am, 58, 918, 10.2106/00004623-197658070-00003 Cook, 1977, Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations, J Bone Joint Surg Am, 59, 496, 10.2106/00004623-197759040-00013 Wu, 1977, Prophylaxis of deep venous trombosis by hydroxychloroquine sulfate and heparin, Surg Gynecol Obstet, 145, 714 Johansson, 1981, Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement, Haemostasis, 10, 89 Bertrand, 1990, Antiaggregation action of cholroquine, Med Trop, 50, 143 Nosal, 1995, Chloroquine inhibits atimulatedplatelets at the arachidonic acid pathway, Thromb Res, 77, 531, 10.1016/0049-3848(95)00028-3 Madow, 1960, Use of antimalarial drugs as “desludging” agents in vascular disease processes, JAMA, 172, 1630, 10.1001/jama.1960.03020150054010 Edwards, 1997, Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice, Circulation, 96, 4380, 10.1161/01.CIR.96.12.4380 Wallace, 1987, Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?, Arthritis Rheum, 30, 1435, 10.1002/art.1780301219 Wallace, 1993, The relevance of antimalarial theraphy with regard to thrombosis, hypercholesterolemia and cytokines in SLE, Lupus, 2, S13, 10.1177/096120339300200104 Petri, 1992, Incidence and predictorsof thrombotic events in SLE: protective role of hydroxychloroquine, Arthritis Rheum, 35, S54 McCarthy, 2000, Hydroxychloroquine (HCQ) treatment in antiphospholipid antibody syndrome (APS): time course of clinical improvement and antiphospholipid antibody (aPL) titer changes over 4 years, Arthiritis Rheum, 43, S1061 Khamashta MA, Wallace DJ, editors. Antimalarial in rheumatology. Lupus. 1996;5 Suppl 1:S1-73. Yoon, 2002, Sufficient evidence to consider hydroxychloroquine as an adjunct therapy in Antiphospholipid Antibody (Hughes’) Syndrome, J Rheumatol, 29, 1574 Wallace, 1994, Antimalarial agents and lupus, Rheum Dis Clin N Am, 20, 243, 10.1016/S0889-857X(21)00233-7 Christiansen, 1956, Treatment of lupus erytematosus with mepacrine: results and relapses during a long observation, Brit J Dermatol, 68, 73, 10.1111/j.1365-2133.1956.tb12788.x Ziff, 1958, Observations on the course and treatment of systemic lupus erythematosus, Arthritis Rheum, 1, 332, 10.1002/art.1780010405 Dubois, 1956, Discoid lupus erythematosus; an analysis of its systemic manifestations, Ann Intern Med, 44, 482, 10.7326/0003-4819-44-3-482 Rudnicki, 1975, The efficacy of antimalarialsin systemic lupus erythematosus, J Rheumatol, 2, 323 1991, A randomized studyof of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus, New Engl J Med, 324, 150, 10.1056/NEJM199101173240303 Tsakonas, 1998, A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus, Lupus, 7, 80, 10.1191/096120398678919778 Williams, 1994, Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythrmatosus, J Rheumatol, 21, 1457 Meinao, 1996, Controlled trial with chloroquine diphosphate in systemic lupus erythematosus, Lupus, 5, 237, 10.1177/096120339600500313 Morand, 1992, Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis, Ann Rheum Dis, 51, 1318, 10.1136/ard.51.12.1318 Petri, 1998, Hydroxychloroquine: past, present, future, Lupus, 7, 65, 10.1191/096120398678919886 Molad, 2002, Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of Israeli cohort, Lupus, 11, 356, 10.1191/0961203302lu203ra Fessler, 2005, Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual, Arthritis Rheum, 52, 1473, 10.1002/art.21039 Jessop, 2004, Drugs for lupus erythematosus (Cochrane Review) Hahn, 2003, Systemic lupus erythematosus and accelerated atherosclerosis, N Engl J Med, 349, 2379, 10.1056/NEJMp038168 Davis, 1996, Role of antimalarial in rheumatoid arthritis –the Brithish experience, Lupus, 5, S37, 10.1177/096120339600500109 Khraishi, 1996, The role of anti-malarial in rheumatoid arthritis– the American experience, Lupus, 5, S41, 10.1177/096120339600500110 Suárez-Almanzor, 2000, Drogas antipalúdicas para la artritis reumatoidea Blackburn, 1995, Tenidap in rheumatoid arthritis. A 24-week double-bindcomparison with hydroxychloroquine-plus-piroxicam and piroxicam alone, Arthritis Rheum, 38, 1447, 10.1002/art.1780381011 Clark, 1993, Hydroxy chloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial, Ann Intern Med, 119, 1067, 10.7326/0003-4819-119-11-199312010-00002 Davis, 1991, Should disease-modifying agents be used in mild rheumatoid arthritis, J Rheumatol, 30, 451, 10.1093/rheumatology/30.6.451 Esdaile, 1995, A randomized trial of hydroxychloroquine in early rheumatoidarthritis: the HERA study, Am J Med, 98, 156, 10.1016/S0002-9343(99)80399-4 Felson, 1992, Use of short-term efficacy/toxicitytradeoffs to select second-line drugs in rheumatoid arthritis: a metaanalysis of published clinicals trials, Arthritis Rheum, 35, 1117, 10.1002/art.1780351003 Csuka, 1986, Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine. A follow-up study, JAMA, 255, 2315, 10.1001/jama.1986.03370170079039 Tialakos, 1986, Low-dose cytotoxic drug combianation therapy in intractablerheumatoid artritis: two years later, Arthritis Rheum, 29, S79 McCarty, 1995, Combinationdrug therapy of seropositive rheumatoid arthritis, J Rheumatol, 22, 1636 Wilke, 1991, Therapy for rheumatoid arthritis: combinationsof disease-modifying drugs and new paradigms of treatment, Semin Arthritis Rheum, 21, 21, 10.1016/0049-0172(91)90048-5 Langevitz, 1989, treatmentwith combined methotrexate, azathioprine and hydroxychloroquine, Br J Rheumatol, 28, 271, 10.1093/rheumatology/28.3.271 Scott, 1989, Combination therapy with gold and hydroxychloroquine in rheumatoidarthritis: a prospective, randomized, placebo-controlled study, Br J Rheumatol, 28, 128, 10.1093/rheumatology/28.2.128 Porter, 1993, Combination therapy in rheumatoidarthritis–no benefit of addition of hydroxychloroquine to patients with asuboptimal response to intramuscular gold therapy, J Rheumatol, 20, 645 Martin, 1982, A combination of D-penicillamine and hydroxychloroquine for the treatment of rheumatoid arthritis, Ann Rheum Dis, 41, 208 Bunch, 1984, Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis, Arthritis Rheum, 27, 267, 10.1002/art.1780270304 Gibson, 1987, Combined D-penicillamine and chloroquine treatment of rheumatoid arthritis-a comparative study, Br J Rheumatol, 26, 279, 10.1093/rheumatology/26.4.279 Faarvang, 1993, Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial, Rheum Dis, 52, 711, 10.1136/ard.52.10.711 Fries, 1990, Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis, Arthritis Rheum, 33, 1611, 10.1002/art.1780331102 Seideman, 1994, Chloroquinereduces the bioavailability of methotrexate in patients with rheumatoidarthritis. A possible mechanism of reduced hepatotoxicity, Arthritis Rheum, 37, 830, 10.1002/art.1780370609 O’Dell, 1996, Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.?, Engl J Med, 334, 1287, 10.1056/NEJM199605163342002 Mottonen, 1999, Comparison of combination therapy with single-drugtherapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group, Lancet, 353, 1568, 10.1016/S0140-6736(98)08513-4 Calguneri, 1999, Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis, Clin Exp Rheumatol, 17, 699 Puolakka, 2004, Impact of initial aggressive drug treatment with a combinationof disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial, Arthritis Rheum, 50, 55, 10.1002/art.11436 Wallace, 1996, The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review, Lupus, 5, S59, 10.1177/096120339600500113 Fox, 1988, Treatment of primary Sjogren’s syndrome with hydroxychloroquine, Am J Med, 85, 62, 10.1016/0002-9343(88)90365-8 Fox, 1996, Treatment of primary Sjögren’ssyndrome with hydroxychloroquine: a retrospective, open-label study, Lupus, 5, S31, 10.1177/096120339600500108 Kruize, 1993, Hydroxychloroquine treatment for primary Sjögren’s syndrome: a two year double blind crossover trial, Ann Rheum Dis, 52, 360, 10.1136/ard.52.5.360 González-López, 2000, Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials, J Rheumatol, 27, 41 Youssef, 1999, Palindromic rheumatism: a response tochloroquine, J Rheumtol, 18, 35 Gladman, 1992, Chloroquine therapy in psoriatic arthritis, J Rheumatol, 19, 1724 Athreya, 1991, Current status of the medical treatment of children with juvenile rheumatoid arthritis, Rheum Dis Clin North Am, 17, 871, 10.1016/S0889-857X(21)00133-2 Bryant, 1995, Hydroxychloroquine in the treatment of erosive osteoarthritis, J Rheumatol, 22, 1527 Rothschild, 1997, Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD, Compr Ther, 23, 327 Ullberg, 1970, Accumulation of chorio-retinotoxic drugs in the foetal eye, Nature, 227, 1257, 10.1038/2271257a0 Hart, 1964, The ototoxicity of chloroquine phosphate, Arch Otolaryngol Head Neck Surg, 80, 407, 10.1001/archotol.1964.00750040419009 Phillips-Howard, 1996, The safety of antimalarial drugs in pregnancy, Safety, 14, 131, 10.2165/00002018-199614030-00001 Buchanan, 1996, Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases, Ann Rheum Dis, 55, 486, 10.1136/ard.55.7.486 Parke, 1996, Hydroxychloroquine in pregnant patients with SLE, Rheumatol, 23, 1715 Goupille, 1997, Grossesse et polyarthrite rhumatoïde, Rev Rhum. (Suppl Pédagogique), 64, 174SP Klinger, 2001, Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases, Lancet, 358, 813, 10.1016/S0140-6736(01)06004-4 Levy, 2001, Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study, Lupus, 10, 401, 10.1191/096120301678646137 Costedoat-Chalumeau, 2003, Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group, Arthritis Rheum, 48, 3207, 10.1002/art.11304 Motta, 2005, Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation, J Perinatol, 25, 86, 10.1038/sj.jp.7211208 Al-Herz, 2002, Survey of antimalarial use in lupuspregnancy and lactation, J Rheumatol, 29, 700 Bernstein, 1983, Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy, Am J Med, 75, 25, 10.1016/0002-9343(83)91267-6 Marmor, 2002, Recommendations on screening for chloroquine and hydroxychloroquine retinopathy, Ophthalmology, 109, 1377, 10.1016/S0161-6420(02)01168-5 Araiza-Casillas, 2004, Factors associated with chloroquine-induced retinopathy in rheumatic diseases, Lupus, 13, 119, 10.1191/0961203304lu514oa Nord, 2004, Hydroxychloroquine cardiotoxicityin systemic lupus erythematosus: a report of 2 cases and review of the literature, Semin Arthritis Rheum, 33, 336, 10.1016/j.semarthrit.2003.09.012 Baguet, 1999, Chloroquine cardiomyopathy with conductiondisorders, Heart, 81, 221, 10.1136/hrt.81.2.221 Cervera, 2001, Cardiac toxicitysecondary to long term treatment with chloroquine, Ann Rheum Dis, 60, 301, 10.1136/ard.60.3.301 Casado, 2002, Antimalarial myopathy: more frecuent than we though? A longitudinal study with 119 patients, Arthritis Rheum, 46, S612 Avina-Zubieta, 1995, Incidenceof myopathy in patients treated with antimalarials. Report of three cases and review of the literature, Br J Rheumatol, 34, 166, 10.1093/rheumatology/34.2.166 Wallace, 2001, Antimalarials-the “real” advance in lupus, Lupus, 10, 385, 10.1191/096120301678646092